Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

AnHeart Approved to Start Two China Trials of Cancer Drug

publication date: Mar 23, 2020

AnHeart Therapeutics of Hangzhou was approved to start two China Phase II trials of taletrectinib, an oral small molecule ROS1/NTRK inhibitor. In late 2018, AnHeart acquired global rights to taletrectinib from Daiichi Sankyo after the Japanese pharma had completed Phase I trials in the US and Japan. AnHeart plans to conduct the China Phase II trials in patients who have non-small cell lung cancer with ROS1 mutations and in patients who have solid tumors with NTRK mutations. In 2019, AnHeart raised $14.6 million in a Series A round from Decheng Capital. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital